Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Newman, L. C.
Right arrow Articles by Solomon, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Newman, L. C.
Right arrow Articles by Solomon, S.
NEUROLOGY 1998;51:307-309
© 1998 American Academy of Neurology

A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine

Lawrence C. Newman, MD, Richard B. Lipton, MD, Christine L. Lay, MD and Seymour Solomon, MD

From the Departments of Neurology (Drs. Newman, Lipton, and Solomon), Psychiatry (Dr. Lipton), Epidemiology and Social Medicine (Dr. Lipton), The Albert Einstein College of Medicine, and the Montefiore Headache Unit (Drs. Newman, Lipton, Lay, Solomon), Bronx, NY.

Address correspondence and reprint requests to Dr. Lawrence C. Newman, Montefiore Headache Unit, 111 East 210th Street, Bronx, New York 10467.

Headaches associated with menstruation are often resistant to abortive and preventative medications. We performed an open-label study in 20 female migraineurs, employing oral sumatriptan perimenstrually as short-term prophylaxis of menstrual migraine. In 126 sumatriptan-treated cycles, headache was absent in 52.4% and reduced in severity by 50% or greater in 42%. Breakthrough headaches were rare and significantly reduced in severity compared with baseline headaches.

Presented in part at the Annual Scientific Meeting of the American Association for the Study of Headache, San Diego, June 1996, and at the International Headache Congress, Amsterdam, June 1997.

Received December 3, 1997. Accepted in final form February 13, 1998.




This article has been cited by other articles:


Home page
 Therapeutic Advances in Neurological DisordersHome page
E. A. MacGregor
Review: Menstrual migraine: therapeutic approaches
Therapeutic Advances in Neurological Disorders, September 1, 2009; 2(5): 327 - 336.
[Abstract] [PDF]

Home page
 Mayo Clin Proc.Home page
I. Garza and J. W. Swanson
Answers to Frequently Asked Questions About Migraine
Mayo Clin. Proc., October 1, 2006; 81(10): 1387 - 1392.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. L. Brandes
The influence of estrogen on migraine: a systematic review.
JAMA, April 19, 2006; 295(15): 1824 - 1830.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. D. Silberstein, A. H. Elkind, C. Schreiber, and C. Keywood
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine
Neurology, July 27, 2004; 63(2): 261 - 269.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
E. Loder
Prophylaxis of menstrual migraine with triptans: Problems and possibilities
Neurology, December 10, 2002; 59(11): 1677 - 1681.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. J. Gilbert and L. C. Newman
A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine
Neurology, April 1, 1999; 52(6): 1300 - 1300.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.